Higher-order structure and protein aggregate characterization of protein therapeutics: Perspectives from good manufacturing practices and regulatory guidance

Biophysics for Therapeutic Protein Development

Volumn , Issue , 2013, Pages 261-281

  Struble, Evi B ^a   Cipollo, John F ^a   Kimchi Sarfaty, Chava ^a   Sauna, Zuben E ^a   Ragheb, Jack A ^b   Marszal, Ewa ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902844615     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-4316-2_11     Document Type: Chapter

References (108)

1. Aguzzi A, O'Connor T (2010) Protein aggregation diseases: pathogenicity and therapeutic perspectives. Nat Rev Drug Discov 9:237-248.
2. Alexander PA, He Y, Chen Y, Orban J, Bryan PN (2007) The design and characterization of two proteins with 88 % sequence identity but different structure and function. Proc Natl Acad Sci USA 104:11963-11968.
3. Anderson DE, Becktel WJ, Dahlquist FW (1990) pH-induced denaturation of proteins: a single salt bridge contributes 3-5 Kcal/Mol to the free energy of folding of T4 lysozyme. Biochemistry 29:2403-2408.
4. Anfinsen CB (1973) Principles that govern the folding of protein chains. Science 181:223-230.
5. Appa RS, Theill C, Hansen L, Moss J, Behrens C, Nicolaisen EM, Klausen NK, Christensen MS (2010) Investigating clearance mechanisms for recombinant activated factor VII in a perfused liver model. Thromb Haemost 104:243-51.
6. Aucamp JP, Cosme AM, Lye GJ, Dalby PA (2005) High-throughput measurement of protein stability in microtiter plates. Biotechnol Bioeng 89:599-607.
7. Baudys M, Uchio T, Mix D, Wilson D, Kim SW (1995) Physical stabilization of insulin by glycosylation. J Pharm Sci 84:28-33.
8. Bee JS, Randolph TW, Carpenter JF, Bishop SM, Dimitrova MN (2011) Effects of surfaces and leachables on the stability of biopharmaceuticals. J Pharm Sci 100:4158-4170.
9. Benoit G, Machuca E, Heidet L, Antignac C (2010) Hereditary kidney diseases: highlighting the importance of classical Mendelian phenotypes. Ann N Y Acad Sci 1214:83-98.
10. Bentham J, Bhattacharya S (2008) Genetic mechanisms controlling cardiovascular development. Ann N Y Acad Sci 1123:10-19.
11. Bolen DW, Baskakov IV (2001) The osmophobic effect: natural selection of a thermodynamic force in protein folding. J Mol Biol 310:955-963.
12. Braeckmans K, Buyens K, Bouquet W, Vervaet C, Joye P, De VF, Plawinski L, Doeuvre L, Angles-Cano E, Sanders NN et al (2010) Sizing nanomatter in biological fluids by fluorescence single particle tracking. Nano Lett 10:4435-4442.
13. Braun A, Kwee L, Labow MA, Alsenz J (1997) Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-Alpha) in normal and transgenic mice. Pharm Res 14:1472-1478.
14. Capriotti E, Fariselli P, Casadio R (2005) I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure. Nucleic Acids Res 33:W306-W310.
15. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G, Fan YX, Kirshner S, Verthelyi D, Kozlowski S et al (2009) Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality. J Pharm Sci 98:1201-1205.
16. Carpenter J, Cherney B, Lubinecki A, Ma S, Marszal E, Mire-Sluis A, Nikolai T, Novak J, Ragheb J, Simak J (2010a) Meeting report on protein particles and immunogenicity of therapeutic proteins: filling in the gaps in risk evaluation and mitigation. Biologicals 38:602-611.
17. Carpenter JF, Randolph TW, Jiskoot W, Crommelin DJ, Middaugh CR, Winter G (2010b) Potential inaccurate quantitation and sizing of protein aggregates by size exclusion chromatography:essential need to use orthogonal methods to assure the quality of therapeutic protein products. J Pharm Sci 99:2200-2208.
18. Castro PM, Ison AP, Hayter PM, Bull AT (1995) The macroheterogeneity of recombinant human interferon-gamma produced by Chinese-hamster ovary cells is affected by the protein and lipid content of the culture medium. Biotechnol Appl Biochem 21:87-100.
19. Cheng J, Randall A, Baldi P (2006) Prediction of protein stability changes for single-site mutations using support vector machines. Proteins 62:1125-1132.
20. Cromwell ME, Hilario E, Jacobson F (2006) Protein aggregation and bioprocessing. AAPS J 8:E572-E579.
21. den Engelsman J, Garidel P, Smulders R, Koll H, Smith B, Bassarab S, Seidl A, Hainzl O, Jiskoot W (2011) Strategies for the assessment of protein aggregates in pharmaceutical biotech product development. Pharm Res 28:920-933.
22. Dresser DW (1962) Specific inhibition of antibody production. II. Paralysis induced in adult mice by small quantities of protein antigen. Immunology 5:378-388.
23. Edgell MH, Sims DA, Pielak GJ, Yi F (2003) High-precision, high-throughput stability determinations facilitated by robotics and a semiautomated titrating fluorometer. Biochemistry 42:7587-7593.
24. Elia AE, Albanese A (2010) Emerging parkinsonian phenotypes. Rev Neurol 166:834-840.
25. England JL, Haran G (2011) Role of solvation effects in protein denaturation: from thermodynamics to single molecules and back. Annu Rev Phys Chem 62:257-277.
26. Ericsson UB, Hallberg BM, Detitta GT, Dekker N, Nordlund P (2006) Thermofluor-based highthroughput stability optimization of proteins for structural studies. Anal Biochem 357:289-298.
27. Fares FA, Suganuma N, Nishimori K, LaPolt PS, Hsueh AJ, Boime I (1992) Design of a longacting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. Proc Natl Acad Sci USA 89:4304-8.
28. Filipe V, Hawe A, Jiskoot W (2010) Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates. Pharm Res 27:796-810.
29. Filipe V, Poole R, Kutscher M, Forier K, Braeckmans K, Jiskoot W (2011) Fluorescence single particle tracking for the characterization of submicron protein aggregates in biological fluids and complex formulations. Pharm Res 28:1112-1120.
30. Fraunhofer W, Winter G (2004) The use of asymmetrical flow field-flow fractionation in pharmaceutics and biopharmaceutics. Eur J Pharm Biopharm 58:369-383.
31. Garrod A (1908) The Croonian lectures on inborn errors of metabolism, lecture II: alkaptonuria. Lancet 2:73-79.
32. Gaudet M, Remtulla N, Jackson SE, Main ER, Bracewell DG, Aeppli G, Dalby PA (2010) Protein denaturation and protein: drugs interactions from intrinsic protein fluorescence measurements at the nanolitre scale. Protein Sci 19:1544-1554.
33. General Chapter <1 > Injections (2012) USP 35-NF 30, pp 33-37.
34. General Chapter <787 > Subvisible particulate matter in therapeutic protein injections [New] (USP36-NF31 1S) (2012) Pharmacopeial Forum 38(3).
35. General Chapter <788 > Particulate Matter in Injections (2012) USP 35-NF 30, pp 339-342.
36. General Chapter <790 > Visible particulates in injections [New] (USP36-NF31 1S) (2012) Pharmacopeial Forum 38(2).
37. Ghaemmaghami S, Oas TG (2001) Quantitative protein stability measurement in vivo. Nat Struct Biol 8:879-882.
38. Gilis D, Rooman M (2000) PoPMuSiC, an algorithm for predicting protein mutant stability changes: application to prion proteins. Protein Eng 13:849-856.
39. Griko YV, Privalov PL, Venyaminov SY, Kutyshenko VP (1988) Thermodynamic study of the apomyoglobin structure. J Mol Biol 202:127-138.
40. Grothe HL, Little MR, Cho AS, Huang AJ, Yuan C (2009) Denaturation and solvent effect on the conformation and fibril formation of TGFBIp. Mol Vis 15:2617-2626.
41. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8:101-112.
42. Harrison M, Maresso K, Broeckel U (2008) Genetic determinants of hypertension: an update. Curr Hypertens Rep 10:488-495.
43. Hartl FU, Hayer-Hartl M (2009) Converging concepts of protein folding in vitro and in vivo. Nat Struct Mol Biol 16:574-581.
44. Hossler P, Khattak SF, Li ZJ (2009) Optimal and consistent protein glycosylation in mammalian cell culture. Glycobiology 19:936-49.
45. Houde D, Peng Y, Berkowitz SA, Engen JR (2010) Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol Cell Proteomics 9:1716-1728.
46. Huang CT, Sharma D, Oma P, Krishnamurthy R (2009) Quantitation of protein particles in parenteral solutions using micro-flow imaging. J Pharm Sci 98:3058-3071.
47. Huang M, Horwitz TS, Zweiben C, Singh SK (2011) Impact of extractables/leachables from filters on stability of protein formulations. J Pharm Sci 100:4617-4630.
48. ICH Harmonized Tripartite Guideline M4Q(R1) (2002) The common technical document for the registration of pharmaceuticals for human use: quality.
49. ICH Harmonized Tripartite Guideline Q10 (2008) Pharmaceutical quality system.
50. ICH Harmonized Tripartite Guideline Q1A(R2) (2003) Stability testing of new drug substances and products.
51. ICH Harmonized Tripartite Guideline Q2(R1) (2005) Validation of analytical procedures: text and methodology.
52. ICH Harmonized Tripartite Guideline Q5B (1995) Quality of biotechnological products: analysis of the expression construct in cells used for production of r-DNA derived protein products.
53. ICH Harmonized Tripartite Guideline Q5C (1995) Quality of biotechnological products: stability testing of biotechnological/biological products.
54. ICH Harmonized Tripartite Guideline Q5E (2004) Comparability of biotechnological/biological products subject to changes in their manufacturing process.
55. ICH Harmonized Tripartite Guideline Q6B (1999) Specifications: test procedures and acceptance criteria for biotechnological/biological products.
56. ICH Harmonized Tripartite Guideline Q8(R2) (2009) Pharmaceutical development.
57. ICH Harmonized Tripartite Guideline Q9 (2005) Quality risk management.
58. Ikemura T (1985) Codon usage and tRNA content in unicellular and multicellular organisms. Mol Biol Evol 2:13-34.
59. Jenkins N, Castro P, Menon S, Ison A, Bull A (1994) Effect of lipid supplements on the production and glycosylation of recombinant interferon-gamma expressed in CHO cells. Cytotechnology 15:209-15.
60. Jorgensen L, Hostrup S, Moeller EH, Grohganz H (2009) Recent trends in stabilising peptides and proteins in pharmaceutical formulation-considerations in the choice of excipients. Expert Opin Drug Deliv 6:1219-1230.
61. Kiese S, Papppenberger A, Friess W, Mahler HC (2008) Shaken, not stirred: mechanical stress testing of an IgG1 antibody. J Pharm Sci 97:4347-4366.
62. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM (2007) A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315:525-528.
63. Klein WL, Krafft GA, Finch CE (2001) Targeting small abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci 24:219-224.
64. Kochanowski N, Blanchard F, Cacan R, Chirat F, Guedon E, Marc A, Goergen JL (2008) Influence of intracellular nucleotide and nucleotide sugar contents on recombinant interferon-gamma glycosylation during batch and fed-batch cultures of CHO cells. Biotechnol Bioeng 100:721-33.
65. Kramer G, Boehringer D, Ban N, Bukau B (2009) The ribosome as a platform for co-translational processing, folding and targeting of newly synthesized proteins. Nat Struct Mol Biol 16:589-597.
66. LaPolt PS, Nishimori K, Fares FA, Perlas E, Boime I, Hsueh AJ (1992) Enhanced stimulation of follicle maturation and ovulatory potential by long acting follicle-stimulating hormone agonists with extended carboxyl-terminal peptides. Endocrinology 131:2514-2520.
67. Lavinder JJ, Hari SB, Sullivan BJ, Magliery TJ (2009) High-throughput thermal scanning: a general, rapid dye-binding thermal shift screen for protein engineering. J Am Chem Soc 131:3794-3795.
68. Lewis JD, Nail SL (1997) The influence of ion exchange chromatography conditions on aggregation of equine IgG. Process Biochem 32:279-283.
69. Liu H, Bulseco GG, Sun J (2006) Effect of posttranslational modifications on the thermal stability of a recombinant monoclonal antibody. Immunol Lett 106:144-153.
70. Luo Q, Joubert MK, Stevenson R, Ketchem RR, Narhi LO, Wypych J (2011) Chemical modifications in therapeutic protein aggregates generated under different stress conditions. J Biol Chem 286:25134-25144.
71. Madsen RE, Cherris RT, Habushnig JG, Hunt DG (2009) Visible particulates in injections-a history and a proposal to revise USP general chapter injections <1> Pharmacopeial Forum 35:1383-1387.
72. Maity H, O'Dell C, Srivastava A, Goldstein J (2009) Effects of arginine on photostability and thermal stability of IgG1 monoclonal antibodies. Curr Pharm Biotechnol 10:761-766.
73. Marszal E, Fowler E (2012) Overview: workshop on predictive science of the immunogenicity aspects of particles in biopharmaceutical products. J Pharm Sci 101:3555-9.
74. Masso M, Vaisman II (2008) Accurate prediction of stability changes in protein mutants by combining machine learning with structure based computational mutagenesis. Bioinformatics 24:2002-2009.
75. McCarthy EF (2011) Genetic diseases of bones and joints. Semin Diagn Pathol 28:26-36.
76. Meager A, Dolman C, Dilger P, Bird C, Giovannoni G, Schellekens H, Thorpe R, Wadhwa M (2011) An assessment of biological potency and molecular characteristics of different innovator and noninnovator interferon-beta products. J Interferon Cytokine Res 31:383-392.
77. Meeker AK, Garcia-Moreno B, Shortle D (1996) Contributions of the ionizable amino acids to the stability of staphylococcal nuclease. Biochemistry 35:6443-6449.
78. Mitra N, Sinha S, Ramya TN, Surolia A (2006) N-linked oligosaccharides as outfitters for glycoprotein folding, form and function. Trends Biochem Sci 31:156-163.
79. Moore WV, Leppert P (1980) Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab 51:691-697.
80. Neuhofer W, Muller E, Grunbein R, Thurau K, Beck FX (1999) Influence of NaCl, urea, potassium and pH on HSP72 expression in MDCK cells. Pflugers Arch 439:195-200.
81. Obici L, Perfetti V, Palladini G, Moratti R, Merlini G (2005) Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 1753:11-22.
82. Parthiban V, Gromiha MM, Schomburg D (2006) CUPSAT: prediction of protein stability upon point mutations. Nucleic Acids Res 34:W239-W242.
83. Pasinelli P, Brown RH (2006) Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 7:710-723.
84. Patel J, Kothari R, Tunga R, Ritter NM, Tunga BS (2011) Stability considerations for biopharmaceuticals, Part 1. Overview of protein and peptide degradation pathways. BioProcess Int 9:20-31.
85. Percy MJ, Rumi E (2009) Genetic origins and clinical phenotype of familial and acquired erythrocytosis and thrombocytosis. Am J Hematol 84:46-54.
86. Pfeil W, Privalov PL (1976) Thermodynamic investigations of proteins. III. Thermodynamic description of lysozyme. Biophys Chem 4:41-50.
87. Philo JS (2009) A critical review of methods for size characterization of non-particulate protein aggregates. Curr Pharm Biotechnol 10:359-372.
88. Rademacher TW, Parekh RB, Dwek RA (1988) Glycobiology. Annu Rev Biochem 57:785-838.
89. Rathore N, Rajan RS (2008) Current perspectives on stability of protein drug products during formulation, fill and finish operations. Biotechnol Prog 24:504-514.
90. Rosgen J (2007) Molecular basis of osmolyte effects on protein and metabolites. Methods Enzymol 428:459-486.
91. Scriver CR (2007) The PAH gene, phenylketonuria, and a paradigm shift. Hum Mutat 28:831-845.
92. Senger RS, Karim MN (2003) Effect of shear stress on intrinsic CHO culture state and glycosylation of recombinant tissue-type plasminogen activator protein. Biotechnol Prog 19:1199-209.
93. Sharp PM, Cowe E, Higgins DG, Shields DC, Wolfe KH, Wright F (1988) Codon usage patterns in Escherichia coli, Bacillus subtilis, Saccharomyces cerevisiae, Schizosaccharomyces pombe, Drosophila melanogaster and Homo sapiens; a review of the considerable within-species diversity. Nucleic Acids Res 16:8207-8211.
94. Shire SJ (2009) Formulation and manufacturability of biologics. Curr Opin Biotechnol 20:708-714.
95. Shukla AA, Gupta P, Han X (2007) Protein aggregation kinetics during Protein A chromatography:case study for an Fc fusion protein. J Chromatogr A 1171:22-28.
96. Sola RJ, Rodriguez-Martinez JA, Griebenow K (2007) Modulation of protein biophysical properties by chemical glycosylation: biochemical insights and biomedical implications. Cell Mol Life Sci 64:2133-2152.
97. Stepanenko OV, Verkhusha VV, Shavlovsky MM, Kuznetsova IM, Uversky VN, Turoverov KK (2008) Understanding the role of Arg96 in structure and stability of green fluorescent protein. Proteins 73:539-551.
98. Stites WE, Byrne MP, Aviv J, Kaplan M, Curtis PM (1995) Instrumentation for automated determination of protein stability. Anal Biochem 227:112-122.
99. Struble EB, Ladner JE, Brabazon DM, Marino JP (2008) New crystal structures of ColE1 Rom and variants resulting from mutation of a surface exposed residue: implications for RNArecognition. Proteins 72:761-768.
100. Tang X, Pikal MJ (2004) Design of freeze-drying processes for pharmaceuticals: practical advice. Pharm Res 21:191-200.
101. Thirumangalathu R, Krishnan S, Ricci MS, Brems DN, Randolph TW, Carpenter JF (2009) Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution. J Pharm Sci 98:3167-3181.
102. Thorens B, Vassalli P (1986) Chloroquine and ammonium chloride prevent terminal glycosylation of immunoglobulins in plasma cells without affecting secretion. Nature 321:618-620.
103. Uchida E, Morimoto K, Kawasaki N, Izaki Y, Abdu Said A, Hayakawa T (1997) Effect of active oxygen radicals on protein and carbohydrate moieties of recombinant human erythropoietin. Free Radic Res 27:311-323.
104. Vazquez-Rey M, Lang DA (2011) Aggregates in monoclonal antibody manufacturing processes. Biotechnol Bioeng 108:1494-1508.
105. Wright A, Morrison SL (1998) Effect of C2-associated carbohydrate structure on Ig effector function:studies with chimeric mouse-human IgG1 antibodies in glycosylation mutants of Chinese hamster ovary cells. J Immunol 160:3393-3402.
106. Xu J, Reumers J, Couceiro JR, De SF, Gallardo R, Rudyak S, Cornelis A, Rozenski J, Zwolinska A, Marine JC et al (2011) Gain of function of mutant P53 by coaggregation with multiple tumor suppressors. Nat Chem Biol 7:285-295.
107. Yin S, Ding F, Dokholyan NV (2007) Modeling backbone flexibility improves protein stability estimation. Structure 15:1567-1576.
108. 1-proteinase inhibitor. Vox Sang 91:309-315.